Performance of Prognostic Heart Failure Models in Patients With Nonischemic Cardiomyopathy Undergoing Ventricular Tachycardia Ablation

This study sought to assess the performance of established risk models in predicting outcomes after catheter ablation (CA) in patients with nonischemic dilated cardiomyopathy (NIDCM) and ventricular tachycardia (VT). A correct pre-procedural risk stratification of patients with NIDCM and VT undergoi...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Clinical electrophysiology 2019-07, Vol.5 (7), p.801-813
Main Authors: Muser, Daniele, Liang, Jackson J., Castro, Simon A., Lanera, Corrado, Enriquez, Andres, Kuo, Ling, Magnani, Silvia, Birati, Edo Y., Lin, David, Schaller, Robert, Supple, Gregory, Zado, Erica, Garcia, Fermin C., Nazarian, Saman, Dixit, Sanjay, Frankel, David S., Callans, David J., Marchlinski, Francis E., Santangeli, Pasquale
Format: Article
Language:English
Subjects:
catheter ablation
dilated cardiomyopathy
electroanatomical mapping
heart failure
ventricular tachycardia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study sought to assess the performance of established risk models in predicting outcomes after catheter ablation (CA) in patients with nonischemic dilated cardiomyopathy (NIDCM) and ventricular tachycardia (VT). A correct pre-procedural risk stratification of patients with NIDCM and VT undergoing CA is crucial. The performance of different pre-procedural risk stratification approaches to predict outcomes of CA of VT in patients with NIDCM is unknown. The study compared the performance of 8 prognostic scores (SHFM [Seattle Heart Failure Model], MAGGIC [Meta-analysis Global Group in Chronic Heart Failure], ADHERE [Acute Decompensated Heart Failure National Registry], EFFECT [Enhanced Feedback for Effective Cardiac Treatment-Heart Failure], OPTIMIZE-HF [Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure], CHARM [Candesartan in Heart Failure-Assessment of Reduction in Mortality], EuroSCORE [European System for Cardiac Operative Risk Evaluation], and PAINESD [Chronic Obstructive Pulmonary Disease, Age > 60 Years, Ischemic Cardiomyopathy, New York Heart Association Functional Class III or IV, Ejection Fraction 
ISSN:2405-500X
2405-5018
DOI:10.1016/j.jacep.2019.04.001